Pacific Shuanglin Bio pharmacy Co Ltd

SHE:000403 China Biotechnology
Market Cap
$1.84 Billion
CN¥13.52 Billion CNY
Market Cap Rank
#7180 Global
#1195 in China
Share Price
CN¥14.23
Change (1 day)
-0.21%
52-Week Range
CN¥13.11 - CN¥25.55
All Time High
CN¥49.14
Categories
Companies in China Biotechnology
About

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in research, development, production, and sales of blood products in China and internationally. The company offers human serum albumin, intravenous human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus and anti-tetanus human immunoglobulin, rabies patient immunoglobulin, human c… Read more

Pacific Shuanglin Bio pharmacy Co Ltd (000403) - Net Assets

Latest net assets as of September 2025: CN¥8.03 Billion CNY

Based on the latest financial reports, Pacific Shuanglin Bio pharmacy Co Ltd (000403) has net assets worth CN¥8.03 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.58 Billion) and total liabilities (CN¥1.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥8.03 Billion
% of Total Assets 83.84%
Annual Growth Rate 17.3%
5-Year Change 718.85%
10-Year Change 1406.69%
Growth Volatility 315.9

Pacific Shuanglin Bio pharmacy Co Ltd - Net Assets Trend (1993–2024)

This chart illustrates how Pacific Shuanglin Bio pharmacy Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Pacific Shuanglin Bio pharmacy Co Ltd (1993–2024)

The table below shows the annual net assets of Pacific Shuanglin Bio pharmacy Co Ltd from 1993 to 2024.

Year Net Assets Change
2024-12-31 CN¥7.92 Billion +6.68%
2023-12-31 CN¥7.42 Billion +8.17%
2022-12-31 CN¥6.86 Billion +8.43%
2021-12-31 CN¥6.33 Billion +554.43%
2020-12-31 CN¥966.91 Million +20.62%
2019-12-31 CN¥801.60 Million +29.40%
2018-12-31 CN¥619.48 Million +10.84%
2017-12-31 CN¥558.88 Million +2.19%
2016-12-31 CN¥546.91 Million +4.08%
2015-12-31 CN¥525.49 Million +14.57%
2014-12-31 CN¥458.65 Million +30.42%
2013-12-31 CN¥351.68 Million +22.25%
2012-12-31 CN¥287.68 Million +1.75%
2011-12-31 CN¥282.74 Million +3.19%
2010-12-31 CN¥274.00 Million +99.07%
2009-12-31 CN¥137.64 Million -22.35%
2008-12-31 CN¥177.26 Million +1686.54%
2007-12-31 CN¥9.92 Million +136.53%
2006-12-31 CN¥-27.16 Million -124.14%
2005-12-31 CN¥112.49 Million -81.32%
2004-12-31 CN¥602.14 Million -28.34%
2003-12-31 CN¥840.33 Million +7.87%
2002-12-31 CN¥779.03 Million +13.26%
2001-12-31 CN¥687.82 Million +14.77%
2000-12-31 CN¥599.28 Million +24.38%
1999-12-31 CN¥481.83 Million +104.48%
1998-12-31 CN¥235.63 Million +14.87%
1997-12-31 CN¥205.14 Million +32.27%
1996-12-31 CN¥155.09 Million +141.00%
1995-12-31 CN¥64.35 Million +11.85%
1994-12-31 CN¥57.54 Million +2.20%
1993-12-31 CN¥56.30 Million --

Equity Component Analysis

This analysis shows how different components contribute to Pacific Shuanglin Bio pharmacy Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 227618313600.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥2.28 Billion 28.72%
Common Stock CN¥731.07 Million 9.23%
Other Comprehensive Income CN¥203.61 Million 2.57%
Other Components CN¥4.71 Billion 59.48%
Total Equity CN¥7.92 Billion 100.00%

Pacific Shuanglin Bio pharmacy Co Ltd Competitors by Market Cap

The table below lists competitors of Pacific Shuanglin Bio pharmacy Co Ltd ranked by their market capitalization.

Company Market Cap
Avino Silver & Gold Mines Ltd
NYSE MKT:ASM
 		$1.03 Billion
Cultural Investment Holdings Co Ltd
SHG:600715
 		$1.03 Billion
LINTEC CORP.
F:57T
 		$1.03 Billion
PNDRY
OTCGREY:PNDRY
 		$1.03 Billion
Aurora Optoelectronics Co Ltd
SHG:600666
 		$1.03 Billion
Iovance Biotherapeutics Inc
NASDAQ:IOVA
 		$1.03 Billion
Anhui Xinlong Electrical Co Ltd
SHE:002298
 		$1.03 Billion
Tompkins Financial Corporation
NYSE MKT:TMP
 		$1.03 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pacific Shuanglin Bio pharmacy Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 7,428,649,258 to 7,924,650,751, a change of 496,001,493 (6.7%).
  • Net income of 745,320,760 contributed positively to equity growth.
  • Dividend payments of 264,625,755 reduced retained earnings.
  • Other comprehensive income increased equity by 203,565,383.
  • Other factors decreased equity by 188,258,895.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥745.32 Million +9.41%
Dividends Paid CN¥264.63 Million -3.34%
Other Comprehensive Income CN¥203.57 Million +2.57%
Other Changes CN¥-188.26 Million -2.38%
Total Change CN¥- 6.68%

Book Value vs Market Value Analysis

This analysis compares Pacific Shuanglin Bio pharmacy Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.31x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 93.39x to 1.31x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 CN¥0.15 CN¥14.23 x
1996-12-31 CN¥0.37 CN¥14.23 x
1997-12-31 CN¥0.49 CN¥14.23 x
1998-12-31 CN¥0.54 CN¥14.23 x
1999-12-31 CN¥1.07 CN¥14.23 x
2000-12-31 CN¥1.31 CN¥14.23 x
2001-12-31 CN¥1.47 CN¥14.23 x
2002-12-31 CN¥1.67 CN¥14.23 x
2003-12-31 CN¥1.73 CN¥14.23 x
2004-12-31 CN¥1.28 CN¥14.23 x
2005-12-31 CN¥-0.03 CN¥14.23 x
2006-12-31 CN¥-0.46 CN¥14.23 x
2007-12-31 CN¥-0.44 CN¥14.23 x
2008-12-31 CN¥0.00 CN¥14.23 x
2009-12-31 CN¥0.01 CN¥14.23 x
2010-12-31 CN¥0.38 CN¥14.23 x
2011-12-31 CN¥0.47 CN¥14.23 x
2012-12-31 CN¥0.43 CN¥14.23 x
2013-12-31 CN¥0.57 CN¥14.23 x
2014-12-31 CN¥0.80 CN¥14.23 x
2015-12-31 CN¥0.93 CN¥14.23 x
2016-12-31 CN¥1.04 CN¥14.23 x
2017-12-31 CN¥1.08 CN¥14.23 x
2018-12-31 CN¥1.20 CN¥14.23 x
2019-12-31 CN¥1.64 CN¥14.23 x
2020-12-31 CN¥1.97 CN¥14.23 x
2021-12-31 CN¥8.95 CN¥14.23 x
2022-12-31 CN¥9.39 CN¥14.23 x
2023-12-31 CN¥10.20 CN¥14.23 x
2024-12-31 CN¥10.85 CN¥14.23 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pacific Shuanglin Bio pharmacy Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 9.41%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 28.08%
  • • Asset Turnover: 0.29x
  • • Equity Multiplier: 1.17x
  • Recent ROE (9.41%) is below the historical average (544.67%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 12.98% 5.89% 0.71x 3.10x CN¥1.92 Million
1996 10.70% 11.58% 0.43x 2.13x CN¥1.09 Million
1997 10.08% 13.13% 0.40x 1.94x CN¥162.68K
1998 9.36% 11.16% 0.37x 2.29x CN¥-1.45 Million
1999 17.74% 22.91% 0.36x 2.13x CN¥34.97 Million
2000 19.79% 28.63% 0.32x 2.14x CN¥54.00 Million
2001 12.72% 18.69% 0.31x 2.22x CN¥16.87 Million
2002 6.36% 9.60% 0.30x 2.19x CN¥-25.76 Million
2003 3.29% 3.68% 0.29x 3.07x CN¥-49.06 Million
2004 -36.70% -26.74% 0.35x 3.92x CN¥-252.22 Million
2005 0.00% -89.33% 0.36x 0.00x CN¥-662.60 Million
2006 0.00% -12.92% 0.40x 0.00x CN¥-67.96 Million
2007 0.00% 5.37% 0.39x 0.00x CN¥53.17 Million
2008 15990.29% 34.90% 0.48x 961.58x CN¥201.88 Million
2009 65.22% 0.50% 0.37x 350.66x CN¥1.97 Million
2010 18.64% 5.36% 0.59x 5.90x CN¥13.55 Million
2011 20.61% 8.91% 0.48x 4.87x CN¥20.96 Million
2012 14.16% 6.93% 0.44x 4.64x CN¥9.57 Million
2013 23.40% 14.71% 0.40x 3.95x CN¥40.25 Million
2014 28.97% 25.03% 0.41x 2.82x CN¥80.23 Million
2015 15.50% 15.50% 0.40x 2.53x CN¥27.52 Million
2016 9.04% 8.93% 0.45x 2.24x CN¥-5.35 Million
2017 3.78% 3.15% 0.52x 2.31x CN¥-35.60 Million
2018 12.54% 9.30% 0.65x 2.07x CN¥16.21 Million
2019 20.05% 17.52% 0.72x 1.59x CN¥80.43 Million
2020 19.26% 17.71% 0.64x 1.71x CN¥89.43 Million
2021 6.18% 19.83% 0.28x 1.12x CN¥-241.50 Million
2022 8.55% 24.41% 0.30x 1.16x CN¥-99.62 Million
2023 8.24% 26.29% 0.27x 1.16x CN¥-130.75 Million
2024 9.41% 28.08% 0.29x 1.17x CN¥-47.14 Million

Industry Comparison

This section compares Pacific Shuanglin Bio pharmacy Co Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,805,909,915
  • Average return on equity (ROE) among peers: 6.60%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Pacific Shuanglin Bio pharmacy Co Ltd (000403) CN¥8.03 Billion 12.98% 0.19x $1.03 Billion
Shenzhen CAU Technology Co Ltd (000004) $183.33 Million -11.06% 0.92x $80.66 Million
Nanhua Bio Medicine Co Ltd (000504) $387.30 Million 7.50% 0.60x $288.51 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518) $642.80 Million -4.58% 0.44x $248.75 Million
Chengzhi Shareholding Co Ltd (000990) $1.65 Billion 1.65% 0.84x $860.44 Million
Hualan Biological EngineeringInc (002007) $4.84 Billion 16.95% 0.08x $2.01 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030) $2.20 Billion 4.62% 0.66x $793.09 Million
Shanghai RAAS Blood Products Co Ltd Class A (002252) $763.33 Million 17.77% 0.08x $3.76 Billion
Baolingbao Biology Co Ltd (002286) $1.81 Billion 11.12% 0.67x $414.37 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $3.77 Billion 15.42% 0.67x $347.52 Million